NO964938L - Flutikason-propionat formuleringer - Google Patents

Flutikason-propionat formuleringer

Info

Publication number
NO964938L
NO964938L NO964938A NO964938A NO964938L NO 964938 L NO964938 L NO 964938L NO 964938 A NO964938 A NO 964938A NO 964938 A NO964938 A NO 964938A NO 964938 L NO964938 L NO 964938L
Authority
NO
Norway
Prior art keywords
pct
fluticasone propionate
formulation
sec
date
Prior art date
Application number
NO964938A
Other languages
English (en)
Other versions
NO964938D0 (no
NO313785B1 (no
Inventor
Dorothy Jill Snell
Li Fong Lam
David Alexander Tainsh
Trevor Leslie Ilott
Original Assignee
Glaxo Wellcome Australia Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Wellcome Australia Ltd filed Critical Glaxo Wellcome Australia Ltd
Publication of NO964938D0 publication Critical patent/NO964938D0/no
Publication of NO964938L publication Critical patent/NO964938L/no
Publication of NO313785B1 publication Critical patent/NO313785B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO19964938A 1994-05-21 1996-11-20 Flutikason-propionatformuleringer, fremgangsmÕte for fremstilling derav, beholder som omfatter formuleringene, samtanvendelse av formuleringene NO313785B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9410222A GB9410222D0 (en) 1994-05-21 1994-05-21 Medicaments
PCT/EP1995/001913 WO1995031964A1 (en) 1994-05-21 1995-05-19 Fluticasone propionate formulations

Publications (3)

Publication Number Publication Date
NO964938D0 NO964938D0 (no) 1996-11-20
NO964938L true NO964938L (no) 1996-11-20
NO313785B1 NO313785B1 (no) 2002-12-02

Family

ID=10755515

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19964938A NO313785B1 (no) 1994-05-21 1996-11-20 Flutikason-propionatformuleringer, fremgangsmÕte for fremstilling derav, beholder som omfatter formuleringene, samtanvendelse av formuleringene

Country Status (28)

Country Link
US (1) US5993781A (no)
EP (1) EP0760649B1 (no)
JP (1) JPH10500420A (no)
KR (2) KR970703132A (no)
CN (1) CN1098680C (no)
AT (1) ATE207734T1 (no)
AU (1) AU710821B2 (no)
BR (1) BR9507746A (no)
CA (1) CA2190763A1 (no)
CY (1) CY2294B1 (no)
CZ (1) CZ285966B6 (no)
DE (1) DE69523587T2 (no)
DK (1) DK0760649T3 (no)
ES (1) ES2164767T3 (no)
FI (1) FI118512B (no)
GB (1) GB9410222D0 (no)
HU (1) HU223316B1 (no)
IL (1) IL113794A (no)
MX (1) MX9605650A (no)
NO (1) NO313785B1 (no)
NZ (1) NZ287425A (no)
PL (1) PL180318B1 (no)
PT (1) PT760649E (no)
RU (1) RU2161485C2 (no)
SI (1) SI0760649T1 (no)
TW (1) TW438604B (no)
WO (1) WO1995031964A1 (no)
ZA (1) ZA954101B (no)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4484247B2 (ja) * 1995-02-24 2010-06-16 エラン ファーマ インターナショナル，リミティド ナノ粒子分散体を含有するエアロゾル
GB9610341D0 (en) * 1996-05-17 1996-07-24 Andaris Ltd Formulation for inhalation
US6946117B1 (en) 1997-09-29 2005-09-20 Nektar Therapeutics Stabilized preparations for use in nebulizers
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6433040B1 (en) 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
SE9704186D0 (sv) 1997-11-14 1997-11-14 Astra Ab New composition of matter
US6241969B1 (en) * 1998-06-26 2001-06-05 Elan Corporation Plc Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
US8820316B2 (en) * 2000-02-11 2014-09-02 Respironics Respiratory Drug Delivery (Uk) Ltd Drug delivery apparatus
PT1280520E (pt) 2000-05-10 2014-12-16 Novartis Ag Pós à base de fosfolípidos para administração de fármacos
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US6858593B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6787532B2 (en) * 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
GB0019172D0 (en) 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
US6759398B2 (en) 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
SI1775305T1 (sl) 2000-08-05 2015-01-30 Glaxo Group Limited S-fluorometil ester 6alfa,9alfa-difluoro-17alfa-((2-furanilkarboksil)oksi)- 11beta-hidroksi-16alfa-metil-3-okso-androst-1,4-dien-17-karbotiojske kisline kot protivnetno sredstvo
US6777399B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6750210B2 (en) 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
US6777400B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
US20030055026A1 (en) * 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
KR100831534B1 (ko) 2001-04-30 2008-05-22 글락소 그룹 리미티드 17.알파 위치에 시클릭 에스테르기를 지닌 항염증성의안드로스탄의 17.베타.-카르보티오에이트 에스테르 유도체
PT1458360E (pt) 2001-12-19 2011-07-13 Novartis Ag Derivados de indole como agonistas do recetor s1p1
EP1471887B1 (en) 2002-02-04 2010-04-21 Elan Pharma International Ltd. Nanoparticulate compositions having lysozyme as a surface stabilizer
WO2003070285A1 (en) 2002-02-19 2003-08-28 Resolution Chemicals Limited Solvent-based sterilisation of pharmaceuticals
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
EP1556091A1 (en) * 2002-10-04 2005-07-27 Elan Pharma International Limited Gamma irradiation of solid nanoparticulate active agents
US20040208833A1 (en) * 2003-02-04 2004-10-21 Elan Pharma International Ltd. Novel fluticasone formulations
EP1454636A1 (en) * 2003-03-04 2004-09-08 Dompé S.P.A. Sterilization of glucocorticoid drug particles for pulmonary delivery
US7811606B2 (en) * 2003-04-16 2010-10-12 Dey, L.P. Nasal pharmaceutical formulations and methods of using the same
US9808471B2 (en) 2003-04-16 2017-11-07 Mylan Specialty Lp Nasal pharmaceutical formulations and methods of using the same
US8912174B2 (en) * 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
EP1626742A1 (en) * 2003-05-22 2006-02-22 Elan Pharma International Limited Sterilization of dispersions of nanoparticulate active agents with gamma radiation
US20040265238A1 (en) * 2003-06-27 2004-12-30 Imtiaz Chaudry Inhalable formulations for treating pulmonary hypertension and methods of using same
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
DE10347994A1 (de) 2003-10-15 2005-06-16 Pari GmbH Spezialisten für effektive Inhalation Wässrige Aerosol-Zubereitung
PE20050941A1 (es) 2003-12-16 2005-11-08 Nycomed Gmbh Suspensiones acuosas de ciclesonida para nebulizacion
DE602005026225D1 (de) 2004-03-12 2011-03-24 Cipla Ltd Sterilisationsprozess für Steroide
GB0410995D0 (en) * 2004-05-17 2004-06-23 Norton Healthcare Ltd Heat sterilization of glucocorticosteroids
GB0425266D0 (en) 2004-11-16 2004-12-15 Norton Healthcare Ltd Pharmaceutical manufacturing process
GB0427568D0 (en) * 2004-12-16 2005-01-19 Resolution Chemicals Ltd Particle-size reduction apparatus, and the use thereof
US20090311335A1 (en) * 2008-06-12 2009-12-17 Scott Jenkins Combination of a triptan and an nsaid
CN102166219B (zh) * 2010-05-25 2013-04-17 杭州天龙药业有限公司 一种鼻腔给药制剂及其应用
EP2847207B1 (en) 2012-05-08 2019-03-27 Nicox Ophthalmics, Inc. Fluticasone propionate nanocrystals
US8765725B2 (en) 2012-05-08 2014-07-01 Aciex Therapeutics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
CN103505412A (zh) * 2012-06-26 2014-01-15 上海臣邦医药科技有限公司 一种吸入用丙酸氟替卡松混悬液的制备方法
US10111957B2 (en) 2012-07-05 2018-10-30 Arven Ilac Snayi ve Ticaret A.S. Inhalation compositions comprising glucose anhydrous
US10105316B2 (en) 2012-07-05 2018-10-23 Arven llac Sanayi Ve Ticaret A.S. Inhalation compositions comprising muscarinic receptor antagonist
WO2014007781A2 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions
WO2014007770A2 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions comprising corticosteroid and sorbitol
DE102012111077A1 (de) * 2012-11-16 2014-05-22 Justus-Liebig-Universität Giessen Optimierung von Vernebelungseigenschaften einer Lösung oder eines Kolloids
US9815865B2 (en) 2013-01-07 2017-11-14 Nicox Ophthalmics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
MY196072A (en) 2014-09-15 2023-03-13 Verona Pharma Plc Liquid Inhalation Formulation Comprising RPL554
EP3807889A1 (en) 2018-06-14 2021-04-21 AstraZeneca UK Limited Methods for treating and preventing symptoms of asthma with a corticosteroid pharmaceutical composition

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225183A (en) * 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
GB2235627B (en) * 1989-09-08 1993-09-01 Glaxo Group Ltd Inhalation medicaments for treating respiratory disorders
US5118494A (en) * 1990-03-23 1992-06-02 Minnesota Mining And Manufacturing Company Use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations
US5658549A (en) * 1991-12-12 1997-08-19 Glaxo Group Limited Aerosol formulations containing propellant 134a and fluticasone propionate
NZ246046A (en) * 1991-12-12 1995-12-21 Glaxo Group Ltd Aerosol comprising a particulate medicament in a fluorocarbon or chlorofluorohydrocarbon and a polar cosolvent
CA2455115C (en) * 1991-12-12 2008-05-27 Glaxo Group Limited Pharmaceutical aerosol formulation
DK0613371T3 (da) * 1991-12-18 2002-05-13 Astrazeneca Ab Ny kombination af formoterol og budesonid
US5301664A (en) * 1992-03-06 1994-04-12 Sievers Robert E Methods and apparatus for drug delivery using supercritical solutions
GB9419536D0 (en) * 1994-09-28 1994-11-16 Glaxo Inc Medicaments
RU2135183C1 (ru) * 1996-02-29 1999-08-27 Государственный научно-клинический центр охраны здоровья шахтеров Способ лечения гормонозависимой бронхиальной астмы

Also Published As

Publication number Publication date
CN1098680C (zh) 2003-01-15
NO964938D0 (no) 1996-11-20
DK0760649T3 (da) 2002-01-28
IL113794A (en) 2000-10-31
EP0760649B1 (en) 2001-10-31
FI964634A0 (fi) 1996-11-20
SI0760649T1 (en) 2002-04-30
KR100361413B1 (ko) 2003-02-19
MX9605650A (es) 1998-05-31
ATE207734T1 (de) 2001-11-15
DE69523587T2 (de) 2002-06-27
PL317225A1 (en) 1997-03-17
ES2164767T3 (es) 2002-03-01
HK1004192A1 (en) 1998-11-20
BR9507746A (pt) 1997-08-19
PT760649E (pt) 2002-04-29
HU9603227D0 (en) 1997-01-28
US5993781A (en) 1999-11-30
CN1148804A (zh) 1997-04-30
PL180318B1 (pl) 2001-01-31
NZ287425A (en) 1998-05-27
HUT76552A (en) 1997-09-29
FI964634L (fi) 1996-11-20
NO313785B1 (no) 2002-12-02
AU710821B2 (en) 1999-09-30
WO1995031964A1 (en) 1995-11-30
DE69523587D1 (de) 2001-12-06
JPH10500420A (ja) 1998-01-13
CZ285966B6 (cs) 1999-12-15
EP0760649A1 (en) 1997-03-12
CY2294B1 (en) 2003-07-04
HU223316B1 (hu) 2004-05-28
KR970703132A (ko) 1997-07-03
AU2614595A (en) 1995-12-18
ZA954101B (en) 1996-01-29
KR970703130A (ko) 1997-07-03
TW438604B (en) 2001-06-07
RU2161485C2 (ru) 2001-01-10
FI118512B (fi) 2007-12-14
IL113794A0 (en) 1995-08-31
CA2190763A1 (en) 1995-11-30
CZ342396A3 (en) 1997-07-16
GB9410222D0 (en) 1994-07-06

Similar Documents

Publication Publication Date Title
ATE207734T1 (de) Fluticasonpropionat-formulierungen
DK0799024T3 (da) Farmaceutisk aerosol indeholdende mindst en sukker
CA2125665A1 (en) Medicaments
PT918507E (pt) Formulacoes em aerossol
GEP20002140B (en) Pharmaceutical Aerosol Composition
ATE246497T1 (de) Fluorchlorkohlenwasserstoffreie aerosolformulierungen
NO971889L (no) Forbindelser og sammensetninger for levering av aktive midler
YU59192A (sh) Formulacija aerosola koje ne sadrže hlorofluorougljenična jedinjenja
WO1994008551A3 (en) Pharmaceutical compositions and methods for treating cold symptoms
IL115920A (en) PHARMACEUTICAL COMPOSITIONS CONTAINING omega-SUBSTITUTED 2,2-DICHLOROALKANECARBOXYLIC ACIDS, SOME SUCH NEW COMPOUNDS AND PROCESS FOR THEIR PREPARATION
HUT76553A (en) Use of gel formulations as dressing agents
DK0633763T3 (da) Kosmetiske eller farmaceutiske sammensætninger indeholdende deacylerede glycerophospholipider til topisk brug
AU8332791A (en) Oral pharmaceutical compositions containing melatonin
ES2123821T3 (es) Formulacion de pulverizacion que tiene un efecto refrescante.
HUT77868A (hu) Imidazopiridin-azolidinonok, ezeket tartalmazó gyógyszerkészítmények, alkalmazásuk és eljárás előállításukra
BR9508021A (pt) Composição farmacêutica para o tratamento de distúrbios esquizofrênicos, uso de um agente imunossupressor, e, processo de tratamento de um paciente esquizofrênico
NO964688L (no) Ny peptid-aktivsubstans og fremstilling av denne
BR9507848A (pt) Composição farmcéutica contendo espiramicina eventualmente em associação com o metronizadol
IL117734A (en) Anellated beta-carbolines their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
MK1K Patent expired